Logos Global Management LP Iovance Biotherapeutics, Inc. Transaction History

Logos Global Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $6.38 Million - $18.3 Million	-1,000,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $12.4 Million - $19.1 Million	1,000,000 New	1,000,000 $16.7 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $8.28 Million - $13.8 Million	-500,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $12.7 Million - $16.6 Million	-625,000 Reduced 55.56%	500,000 $12.3 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $18.4 Million - $37.2 Million	1,125,000 New	1,125,000 $29.3 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $6.73 Million - $10.1 Million	-247,248 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $521,815 - $1.04 Million	26,705 Added 12.11%	247,248 $7.4 Million
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $3.96 Million - $6.49 Million	220,543 New	220,543 $6.11 Million

323

239M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.63B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.